Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension

Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertension - Tolvaptan for right heart failure due to pulmonary hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010196

Enrollment

Registered

2013-03-10

Start date

2013-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary hypertension

Interventions

The administration of tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Chronic right heart failure due to pulmonary hypertension 2) Physical findings of fluid retention 3) Loop diuretic administration of furosemide 60mg in a day 4) Written informed consent is obtained

Exclusion criteria

Exclusion criteria: 1) Systolic blood pressure is less than or equal to 70mmHg 2) There is a history of hypersensitivity for similar compounds (such as hydrochloride Mozabaputan) components or tolvaptan 3) Anuria 4) A subject is difficult to feel thirst or water intake 5) Hypernatremia 6) There is a possibility that a subject is pregnant or pregnant women 7) Hepatic coma 8) There is a history of hypersensitivity to sulfonamide derivatives 9) Tolvaptan has been administered from admission to registration 10) Acute coronary syndromes 11) Scheduled to perform coronary angioplasty during follow-up period 12) Physicians and other staff have been deemed inappropriate for registration of this study

Design outcomes

Primary

Measure	Time frame
The usage dose of loop diuretics.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026